4D Molecular Therapeutics Inc

NASDAQ:FDMT 4:00:00 PM EDT

4.50

+0.14 (+3.21%)

5:35:15 PM EDT: $4.68 +0.18 (+4.00%)

Market Cap (Intraday)	208.46M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.39 Million
Adjusted EPS	-$0.73

See more estimates

10-Day MA	$4.20
50-Day MA	$3.41
200-Day MA	$6.68

See more pivots

4D Molecular Therapeutics Inc Stock, NASDAQ:FDMT

5858 Horton Street, Suite 455, Emeryville, California 94608

United States of America

Phone: +1.510.505.2680

Number of Employees: 227

http://www.4dmoleculartherapeutics.com

Description

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.